Sign In   |   Register


Breaking News:

Breaking News

8-20-19 Canbiola, Inc. (OTCQB:CANB)
Canbiola Reports Second Quarter 2019 Results

Click Here For Press Release

8-7-19 Trickle Research issues update and allocation increase to 6
Camino Minerals Corp  OTC: CAMZF TSXV: COR.V
12-24 Month Price Target $0.90

Click Here For Update Report

Trickle Research issues update and allocation increase to 7
AzurRx Biopharma, Inc.  7-11-19
12-24 Month Price Target $10.25

Click Here for Update Report

6-6-19 Greenridge Global Equity Research
Issues Update
Guangdong Land Holdings, Ltd.
Maintaining rating and Buy target HK$ 4.75
Click Here>>

6-4-19 Trickle Research Issues Allocation Update Report
Summit Wireless Technologies, Inc. Nasdaq (WISA) 
12-24 Month Price Target $9.25

Allocation 5
Click Here>>

4-9-19 Trickle Research Initiates Research
H Source Holdings, Ltd., TSXV (HSI.V) OTCQB (HSCHF) 
12-24 Month Price Target $0.19
Click Here>>

5-20-18 Trickle Research Issues Update Report
Alvopetro Energy, Ltd., TSXV (ALV.V) OTC (ALVOF) 
12-24 Month Price Target $1.10
Clcik Here>>

4-29-19 Greenridge Global Equity Research Issues Updates
Guangdong Land Holdings, Ltd.
Click Here>>

Chardan Research Earnings Update 4-19-19
  Social Reality Inc. (SRAX)
Target Price $10.00

Click Here for Report

4-17-19 Canbiola, Inc. (CANB)
Canbiola Announces Fourth Quarter and Full Year 2018 Results

Click Here for Complete Release

Trickle Research Earnings Update 4-16-19
  Social Reality Inc. (SRAX)
12-24 Month Target Price $15.00

Click Here for Report

Trickle Research Fiscal 2018
& Merger Announcement Update Update 4-10-19
12-24 Month Target Price $8.75

Click Here for Report

3-28-2019 Endurance Exploration Group, Inc. (EXPL)

Blue Water Ventures International, Inc. and Project Partner Endurance Exploration Group, Inc. Announce Preparations for 2019 Operations

Read Complete Press Release>>

3-11-19 Canbiola, Inc. (CANB) Canbiola is Registered and Active in the GSA’s System for Award Management (SAM) and Department of Defense (DOD)
Read Complete Press Release>>

Trickle Research issues update of
AzurRx Biopharma, Inc.  2-26-19
12-24 Month Price Target $10.25

Click Here for Update Report

Trickle Research Earnings Update 2-9-19
  Social Reality Inc. (SRAX)
12-24 Month Target Price $9.25

Click Here for Report




  Black Swan Research
Research Coverage 4-19
SMM is now hosting Equity Research and updates from top tier research providers:           
 Trickle Research
Click here to Subscribe to Trickle Research 
 Falcon Strategic Research
 Consilium Global Research
 Click Here to Subscribe to Black Swan Research

Black Swan Newsletter



August 2019

Click here to view

Our goal with the Black Swan Connection is to provide our subscribers, investors and financial professional compatriots outstanding investment insight that is a step above and outside of what will normally be found in mainstream financial press. To that end we have brought together seasoned, successful, and some of the brightest professionals in their respective fields to provide the articles and advice that is based on decades of practice in the field.

Breaking News

Tesla is a story we’ve been covering for a while- No good news here…..

Slumping Tesla Stock Headed Into Test of 2019 Low

Controversial automaker Tesla, Inc. (TSLA) is slumping badly in this tough summer market, dropping like a rock after a six-week oversold rally reversed in July at major resistance between $250 and $270. Adding to growing shareholder anxiety, the stock just broke intermediate support near $230, exposing a second trip into the psychological $200 level and a critical test at June's three-year low at $176.99. First, Wall Street is concerned Tesla doesn't have a viable path to profitability after it reported a much greater-than-expected loss in July's quarterly report.

Read Full Commentary


Feature Article

For Microcaps…Its Rough Out There

By: Dave Lavigne

August 2019

I have been providing independent microcap stock research under my own labels since 2002.  Prior to that, I provided the same on the sell side for small regional broker dealers, and that included research as a part of those entities’ corporate finance due diligence. I have been at this a while.

Over those periods that I was preparing research for “public consumption” I kept a track record of  sorts comparing my research universe to that of the performances of three major U.S. equity indices; the Dow Jones Industrial Average, the NASDAQ and the S&P 500. Over much of that period, (and over reasonable periods of time) my research universes typically outperformed those indices, and often by meaningful margins.  As a matter of full disclosure, there are a number of nuances that impact the relevance of those comparisons (transaction costs, spreads, liquidity etc.), so I fully submit, while the stock picks as whole have performed well, I am certainly no guru, and comparing the picks to those indices has some holes. 

Read Complete Article

8-2-19 Canbiola, Inc. (OTCQB:CANB)

Canbiola Launches Dedicated Canbiola-Branded CBD Dispensing Machine

Initial 25 Units Will Target Medical Offices

HICKSVILLE, NY, Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer, and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, isolate, gel caps, and concentrate announced today the launch of its own Canbiola-branded CBD product dispensing machine. An initial order for the first 25 units has been placed with the installations expected to occur in August and September.

Read Complete Press Release


7-16-19 Antibe Therapeutics, Inc. TSXV:ATE, OTCQB:ATBPF)

Antibe Therapeutics Reports 2019 Year-End Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF) filed its financial and operating results on Tuesday, July 16 for the fourth quarter and the year ended March 31, 2019. The Company's audited 2019 consolidated financial statements, MD&A and AIF are available on SEDAR.

About Antibe Therapeutics Inc.
Antibe develops safer, non-addictive medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation.

Read Complete Press Release

InvestorsHub News Wire:



Weekly Update: Aug 21st, 2019

Breaking News

FX Empire  Aug-19-19

S&P 500 Price Forecast – Stock markets head towards massive resistance

The S&P 500 rallied a bit during the trading session on Monday, slamming into the 50 day EMA by the time traders started to settle into their desks. The question now is whether or not we can continue from here, because the 50 day EMA has attracted a lot of selling pressure over the last several sessions, just as the 200 day EMA continues to attract a lot of buying pressure. I think at this point though, we need to see is a break above the 2950 level to feel a little bit more confident about going long of this market.

Read Complete Article

Great Article on Picking Junior Mining Companies-

Mike Sheikh -Falcon Strategic Research

Gold Sector Snapshot – Criteria for Picking Junior Miners

  • Gold prices appreciated 18% YTD
  • Uncertainty in the world economy driving prices
  • Rising prices helping increase feasibility of shut in mines
  • Criteria to picking the ideal Junior Miner

Gold prices are on an upswing and investors looking to park some money in the sector should be aware of some of the nuances of gold investing.  Gold has appreciated 18% in part due to the China trade war dialog and the political uncertainty around the world.  In addition, increases in volatility cause people to desire gold more.  The Junior miners have moved in pretty much lock step with gold prices but there seems to be small divergence that investors might want to capitalize in buying assets at a discount.    This article is going to explore some of the methods used to evaluate Junior Miners.  

Read Complete Report


8-20-19 Canbiola, Inc. (OTCQB:CANB)
Canbiola Reports Second Quarter 2019 Results

Closed $3.9 Million Equity Raise Completed

HICKSVILLE, N.Y., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer and seller of variety of hemp-derived THC-Free Cannabidiol (CBD) Isolate products such as oils, drops/tinctures, creams, moisturizers, chews, and capsules, announced today the company's financial results for the second quarter ended June 30, 2019.

Key Financial Highlights for Q2 2019:

  • Revenues increased by 311% to $633,579
  • Gross margin of 52.8%
  • Operating loss of $1,435,289, included $959,948 in non-cash stock-based compensation
  • Closed $3,936,700 cash raised subsequent to the end of the quarter

Read Complete Press Release

Community Search
Sign In